<--- Back to Details
First PageDocument Content
Chemistry / Alcohols / Venlafaxine / Food and Drug Administration / Propofol / Hospira / MedWatch / Adverse effect / Daptomycin / Medicine / Pharmacology / Health
Date: 2015-03-03 14:26:39
Chemistry
Alcohols
Venlafaxine
Food and Drug Administration
Propofol
Hospira
MedWatch
Adverse effect
Daptomycin
Medicine
Pharmacology
Health

Aurobindo 300mg gabapentin capsules On Nov. 21, 2014, Aurobindo, recalled one lot (GESB14011-A) of gabapentin capsules, 300mg, which were distributed in 100-unit bottles under the Northstar label (NDCEmpt

Add to Reading List

Source URL: chpw.org

Download Document from Source Website

File Size: 42,69 KB

Share Document on Facebook

Similar Documents

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

ZAI Lab announces appointment of Dr. James Yan as Executive Vice President of Early Development and Drug Safety Shanghai, China – October – Zai Lab Limited (Zai Lab), an innovative biotech company based in Ch

ZAI Lab announces appointment of Dr. James Yan as Executive Vice President of Early Development and Drug Safety Shanghai, China – October – Zai Lab Limited (Zai Lab), an innovative biotech company based in Ch

DocID: 1qDbm - View Document

United States Court of Appeals for the Federal Circuit ______________________ THE MEDICINES COMPANY, Plaintiff-Appellant

United States Court of Appeals for the Federal Circuit ______________________ THE MEDICINES COMPANY, Plaintiff-Appellant

DocID: 1qAvA - View Document

April 29, Sanofi Rebuffed in $9.3 Billion Proposal to Acquire Medivation Sanofi has made a non­binding proposal to acquire Medivation, Inc., a San Francisco­based biopharmaceutical company, for

April 29, Sanofi Rebuffed in $9.3 Billion Proposal to Acquire Medivation Sanofi has made a non­binding proposal to acquire Medivation, Inc., a San Francisco­based biopharmaceutical company, for

DocID: 1q9zg - View Document

Products Approved in FY 2010: New Drugs Review Approval Date No. Category  Brand Name

Products Approved in FY 2010: New Drugs Review Approval Date No. Category Brand Name

DocID: 1pe3I - View Document